#Article in #MedComm
A Phase II Study of #Sitravatinib Combined With #Tislelizumab Plus Docetaxel for Acquired #Resistance to PD-(L)1 in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer doi.org/10.1002/mco2...
#AcquiredResistance #Tcell #immunotherapy #PSI #TCR
0
0
0
0